Lamisil

Terbinafine Hydrochloride, the active ingredient in Lamisil, is an allylamine antifungal presented as a topical formulation for topical use. It treats superficial fungal infections of the skin such as athlete's foot, ringworm and jock itch in adults and children. GNH USA supplies Lamisil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamisil (terbinafine) is indicated for the treatment of superficial dermatophyte infections of the skin.

- Tinea pedis: alleviates itching and clears fungal infection of the feet. - Tinea corporis: resolves ring‑shaped lesions on the body. - Tinea cruris: treats fungal infection of the groin area. - Other superficial dermatophyte infections: eliminates fungal growth on skin surfaces.

Lamisil may cause local skin reactions and, rarely, systemic effects.

Common Side Effects: - Itching at the application site. - Redness or erythema. - Burning sensation. - Dryness or scaling of the skin. - Mild irritation or stinging. - Contact dermatitis.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Extensive rash or Stevens‑Johnson syndrome. - Bullous pemphigoid. - Significant liver enzyme elevation. - Systemic hypersensitivity. - Unexplained fever or malaise.

Before using Lamisil, consider the following safety measures. - Pregnancy: consult a healthcare professional before application. - Breastfeeding: discuss potential risks with a physician. - Age: use with caution in children; follow pediatric guidance. - Skin condition: avoid applying to broken or inflamed skin. - Allergy: discontinue use if severe irritation or allergic reaction occurs. - Store at room temperature: keep in the original container, protect from moisture and light.

Terbinafine topical may interact with systemic agents; monitor accordingly.

Major Interactions (Avoid): - Concurrent systemic terbinafine therapy: risk of cumulative exposure. - Systemic azole antifungals (e.g., itraconazole, ketoconazole): may increase hepatic load.

Moderate Interactions (Monitor Closely): - Warfarin: monitor coagulation parameters. - Oral contraceptives: possible reduced efficacy. - Other topical agents causing irritation: assess skin tolerance. - CYP2D6 inhibitors (if systemic absorption is significant): observe for adverse effects.